TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells

The novel emerged SARS-CoV-2 has rapidly spread around the world causing acute infection of the respiratory tract (COVID-19) that can result in severe disease and lethality. For SARS-CoV-2 to enter cells, its surface glycoprotein spike (S) must be cleaved at two different sites by host cell protease...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Life science alliance Ročník 3; číslo 9; s. e202000786
Hlavní autori: Bestle, Dorothea, Heindl, Miriam Ruth, Limburg, Hannah, Van Lam van, Thuy, Pilgram, Oliver, Moulton, Hong, Stein, David A, Hardes, Kornelia, Eickmann, Markus, Dolnik, Olga, Rohde, Cornelius, Klenk, Hans-Dieter, Garten, Wolfgang, Steinmetzer, Torsten, Böttcher-Friebertshäuser, Eva
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Life Science Alliance 01.09.2020
Life Science Alliance LLC
Predmet:
ISSN:2575-1077, 2575-1077
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:The novel emerged SARS-CoV-2 has rapidly spread around the world causing acute infection of the respiratory tract (COVID-19) that can result in severe disease and lethality. For SARS-CoV-2 to enter cells, its surface glycoprotein spike (S) must be cleaved at two different sites by host cell proteases, which therefore represent potential drug targets. In the present study, we show that S can be cleaved by the proprotein convertase furin at the S1/S2 site and the transmembrane serine protease 2 (TMPRSS2) at the S2′ site. We demonstrate that TMPRSS2 is essential for activation of SARS-CoV-2 S in Calu-3 human airway epithelial cells through antisense-mediated knockdown of TMPRSS2 expression. Furthermore, SARS-CoV-2 replication was also strongly inhibited by the synthetic furin inhibitor MI-1851 in human airway cells. In contrast, inhibition of endosomal cathepsins by E64d did not affect virus replication. Combining various TMPRSS2 inhibitors with furin inhibitor MI-1851 produced more potent antiviral activity against SARS-CoV-2 than an equimolar amount of any single serine protease inhibitor. Therefore, this approach has considerable therapeutic potential for treatment of COVID-19.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Dorothea Bestle, Miriam Ruth Heindl, and Hannah Limburg contributed equally to this work
ISSN:2575-1077
2575-1077
DOI:10.26508/lsa.202000786